## 1 Prenatal exposure to environmental contaminants is associated with altered

## 2 cord serum metabolite profiles in future immune-mediated diseases

- 3
- 4 Bagavathy Shanmugam Karthikeyan,<sup>1,2</sup> Tuulia Hyötyläinen,<sup>1</sup> Tannaz Ghaffarzadegan,<sup>1</sup> Eric
- 5 Triplett,<sup>3</sup> Matej Orešič,<sup>2,4,\*</sup> Johnny Ludvigsson<sup>5</sup>
- 6
- <sup>7</sup> <sup>1</sup>School of Science and Technology, Örebro University, SE-702 81 Örebro, Sweden
- <sup>8</sup> <sup>2</sup>School of Medical Sciences, Faculty of Medicine and Health, Örebro University, SE-702 81
- 9 Örebro, Sweden
- <sup>3</sup>Department of Microbiology and Cell Science, Institute of Food and Agricultural Sciences
- 11 University of Florida, Gainesville, 32611-0700, FL, USA
- <sup>4</sup>Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, FI-20520,
- 13 Finland
- <sup>14</sup> <sup>5</sup>Crown Princess Victoria's Children's Hospital and Division of Pediatrics, Department of
- 15 Biomedical and Clinical Sciences, Linköping University, Linköping, SE-581 85, Sweden
- 16
- 17 \*Correspondence:
- 18
- Matej Orešič; School of Science and Technology, Örebro University, 702 81 Örebro, Sweden.
  Email: <u>matej.oresic@oru.se</u>; Phone: +46 76 9464459. ORCID ID: 0000-0002-2856-9165
  (editorial correspondence)
- -- (••••••••••••••••••••••••
- 22
- 23

#### Abstract 24

Prenatal exposure to environmental contaminants is a significant health concern because it has the 25 potential to interfere with host metabolism, leading to adverse health effects in early childhood 26 and later in life. Growing evidence suggests that genetic and environmental factors, as well as their 27 interactions, play a significant role in the development of autoimmune diseases. In this study, we 28 hypothesized that prenatal exposure to environmental contaminants impacts cord serum 29 metabolome and contributes to the development of autoimmune diseases. We selected cord serum 30 samples from All Babies in Southeast Sweden (ABIS) general population cohort, from infants who 31 later developed one or more autoimmune-mediated and inflammatory diseases: celiac disease 32 (CD), Crohn's disease (IBD), hypothyroidism (HT), juvenile idiopathic arthritis (JIA), and type 1 33 diabetes (T1D) (all cases, N = 62), along with matched controls (N = 268). Using integrated 34 exposomics and metabolomics mass spectrometry (MS) based platforms, we determined the levels 35 of contaminants and metabolites. Differences in exposure levels were found between the controls 36 and those who later developed various diseases. High contaminant exposure levels were associated 37 with changes in metabolome, including amino acids and free fatty acids. Specifically, we identified 38 39 marked associations between metabolite levels and exposure levels of deoxynivalenol (DON), bisphenol S (BPS), and specific per- and polyfluorinated substances (PFAS). Our study suggests 40 that prenatal exposure to specific environmental contaminants alters the cord serum metabolomes, 41 which, in turn, might increase the risk of various immune-mediated disease later in life. 42

43

Keywords: autoimmune disease; environmental contaminants; exposome; lipidomics; 44 metabolomics; type 1 diabetes. 45

## 47 Introduction

Exposure to environmental contaminants contributes to the global burden of many chronic diseases 48 (Chew et al. 2023; Cui et al. 2016; Diseases and Injuries 2020; Landrigan et al. 2016; Shaffer et 49 al. 2019). Over the past few decades, the prevalence of autoimmune diseases increased in both 50 developed and developing countries, resulting in a high disease burden (Berhan et al. 2011; 51 Carstensen et al. 2020; Eaton et al. 2007; Harjutsalo et al. 2013; Patterson et al. 2009). 52 Autoimmune diseases are often manifested in early childhood and are also common among the 53 pregnant mothers (Eaton et al. 2007; Tincani et al. 2016). They are chronic, impact child growth 54 and development and require long-term management and care (Rosenblum et al. 2012; Wilson et 55 al. 2016). Many studies suggest that a combination of genetic predisposition, environmental and 56 maternal factors as well as their interactions play a significant role in the etiology of autoimmune 57 diseases (Ellis et al. 2014; Oresic et al. 2013; Oresic et al. 2008; Rewers and Ludvigsson 2016; 58 Sen et al. 2019; Sen et al. 2020; Sinisalu et al. 2020; Virolainen et al. 2023). 59

Exposure of humans to environmental chemicals begins already during the "sensitive window" of 60 61 human early development, including the prenatal stage (Buhimschi and Buhimschi 2012; Karthikeyan et al. 2021; Landrigan and Goldman 2011; Robinson and Vrijheid 2015). Prenatal 62 exposure to PFAS and other contaminants have been associated with abnormal metabolism and 63 later progression to autoimmune diseases such as T1D (McGlinchey et al. 2020), CD (Sen et al. 64 2019; Sinisalu et al. 2020), IBD (Filimoniuk et al. 2020) later. PFAS exposure, for instance, alters 65 the levels of phospholipids and contributes to the risk of T1D (McGlinchey et al. 2020). Although 66 most autoimmune diseases share common pathogenicity and genetic risk factors (Ilonen et al. 67 2016; Sen et al. 2019), their underlying pathogenic mechanisms are poorly understood. Beside 68 69 exposure to environmental chemicals, perinatal factors such as low birth weight (Katsarou et al. 2017), the gut microbiome (Belteky et al. 2023; Khan and Wang 2019; Kindgren et al. 2023; Kostic 70 et al. 2015; Vatanen et al. 2018; Weis 2018) and maternal diet (Johnson et al. 2021; Johnson et al. 71 72 2019; Virtanen et al. 2012) are also attributed to the progression of autoimmune diseases.

Given the potential impact of exposure to environmental contaminants and the role of maternal 73 factors in the progression of autoimmune diseases (Hyotylainen et al. 2023), it is important to 74 characterize the prenatal and early-life exposome to better understand the pathogenesis of 75 autoimmune diseases. Herein, we hypothesized that exposure to environmental contaminants 76 impacts cord serum metabolome, which may contribute to the development of one or more 77 autoimmune diseases in the general population cohort (All Babies In Southeast Sweden, ABIS) 78 (Ludvigsson et al. 2001; Nygren et al. 2015). We quantified levels of contaminants and metabolite 79 profiles from cord serum collected at birth, using integrated exposomics and metabolomics 80 81 approaches. We investigated (i) the levels of exposure and significant differences between controls and cases, (ii) associations of contaminant exposure with cord serum metabolic profiles, and (iii) 82 the impact of contaminant exposure levels on cord serum metabolic profiles. 83

## 84 Materials and methods

#### 85 Study design

ABIS, a general population cohort consists of 17000 children born 1<sup>st</sup> of Oct 1997- 1<sup>st</sup> of Oct 1999, 86 followed prospectively with regular follow-ups. ABIS is connected to the Swedish National 87 Diagnosis Register which give information about diagnosis of autoimmune disease. Stool samples 88 89 were collected from ca 1800 individuals at 1 year of age, and microbiome studies have been performed (Belteky et al. 2023; Hyotylainen et al. 2023). The present study includes subjects 90 91 (N=62) from this group who later developed one or more autoimmune and inflammatory diseases 92 such as cCeliac disease (CD), Crohns disease (IBD), hypothyroidism (HT), juvenile idiopathic arthritis (JIA) and type1 diabetes (T1D) along with their matching controls (N=268). The cord 93 blood samples collected during birth were subjected to metabolomics analysis. Fig. 1 summarizes 94 95 the study design and integrated workflow.

This study was performed in accordance with the Declaration of Helsinki. The ABIS study was approved by the Research Ethics Committees of the Faculty of Health Sciences at Linköping

University, Sweden, 1997/96287 and 2003/03-092 and the Medical Faculty of Lund University,
Sweden (DNR 99227, DNR 99321). All participating parents gave their informed consent to
participate in ABIS after oral, written and video information. ABIS connection to national register
approved by the Research Ethics Committees of the Faculty of Health Sciences at Linköping
University, Sweden, DNR 05-513, and 2018/380-32.

#### 103 Analysis of metabolome and environmental contaminants

A total of 360 cord blood samples were randomized and analyzed as described below. Shortly, two 104 methods were applied for separate extraction of lipids and polar/semipolar metabolites and the 105 extracts were then analyzed using an ultra-high-performance liquid chromatography quadrupole 106 time-of-flight mass spectrometry (UHPLC-QTOFMS) as described previously (Hyotylainen et al. 107 2023) and the data were processed using MZmine 2.53 (Pluskal et al. 2010). Quantification was 108 performed using calibration curves and the identification was done with a custom data base, with 109 110 identification levels 1 and 2 (Metabolomics Standards Initiative). Quality control was performed by analyzing pooled quality control samples. In addition, extracted blank samples, standards 111 compounds, and reference plasma (NIST SRM 1950); purchased from the National Institute of 112 Standards and Technology at the US Department of Commerce (Washington, DC, USA)) were 113 analyzed as part of the quality control procedure. 114

#### 115 Analysis of molecular lipids

10 µl of serum was mixed with 10 µl 0.9% NaCl and extracted with 120 µl of CHCl<sub>3</sub>: MeOH (2:1, 116 v/v) solvent mixture containing internal standard mixture (c = 2.5  $\mu$ g/ml; 1,2-diheptadecanoyl-sn-117 glycero-3-phosphoethanolamine (PE(17:0/17:0)), N-heptadecanoyl-D-erythro-118 sphingosylphosphorylcholine (SM(d18:1/17:0)), N-heptadecanoyl-D-erythro-sphingosine 119 (Cer(d18:1/17:0)),1,2-diheptadecanoyl-sn-glycero-3-phosphocholine (PC(17:0/17:0)), 1-120 heptadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine (LPC(17:0)) and 1-palmitoyl-d31-2-121 oleoyl-sn-glycero-3-phosphocholine (PC(16:0/d31/18:1)) triheptadecanoylglycerol 122 and,

123 (TG(17:0/17:0)). The samples were vortexed and let stand on the ice for 30 min before 124 centrifugation (9400 rcf, 3 min). 60  $\mu$ l of the lower layer of was collected and diluted with 60  $\mu$ l 125 of CHCl<sub>3</sub>: MeOH. The samples were kept at -80 °C until analysis.

Samples were analyzed by UHPLC-QTOFMS (Agilent Technologies; Santa Clara, CA, USA). The analysis was carried out on an ACQUITY UPLC BEH C18 column (2.1 mm  $\times$  100 mm, particle size 1.7 µm) by Waters (Milford, USA). he eluent system consisted of (A) 10 mM NH<sub>4</sub>Ac in H<sub>2</sub>O and 0.1% formic acid and (B) 10 mM NH<sub>4</sub>Ac in ACN: IPA (1:1) and 0.1% formic acid. The gradient was as follows: 0-2 min, 35% solvent B; 2-7 min, 80% solvent B; 7-14 min 100% solvent B. The flow rate was 0.4 ml/min.

The following steps were applied in data processing with MZmine 2.53: (i) Mass detection with a 132 noise level of 1000, (ii) Chromatogram builder with a minimum time span of 0.08 min, minimum 133 height of 1000 and a m/z tolerance of 0.006 m/z or 10.0 ppm, (iii) Chromatogram deconvolution 134 using the local minimum search algorithm with a 70% chromatographic threshold, 0.05 min 135 minimum RT range, 5% minimum relative height, 1200 minimum absolute height, a minimum 136 ration of peak top/edge of 1.2 and a peak duration range of 0.08–5.0, (iv), Isotopic peak grouper 137 with a m/z tolerance of 5.0 ppm, RT tolerance of 0.05 min, maximum charge of 2 and with the 138 most intense isotope set as the representative isotope, (v) Join aligner with a m/z tolerance of 0.009 139 or 10.0 ppm and a weight for of 2, a RT tolerance of 0.15 min and a weight of 1 and with no 140 requirement of charge state or ID and no comparison of isotope pattern, (vi) Peak list row filter 141 with a minimum of 10% of the samples (vii) Gap filling using the same RT and m/z range gap 142 filler algorithm with an m/z tolerance of 0.009 m/z or 11.0 ppm, (vii) Identification of lipids using 143 a custom database search with an m/z tolerance of 0.008 m/z or 8.0 ppm and a RT tolerance of 144 0.25 min. Identification of lipids was based on an in-house librarybased on LC-MS/MS data on 145 retention time and mass spectra. The identification was done with a custom data base, with 146 identification levels 1 and 2, *i.e.*, based on authentic standard compounds (level 1) or based on 147 MS/MS identification (level 2). 148

149	Quantification of lipids was performed using a 7-point internal calibration curve (0.1-5 $\mu$ g/mL)
150	using the following lipid-class specific authentic standards: using 1-hexadecyl-2-(9Z-
151	octadecenoyl)-sn-glycero-3-phosphocholine (PC(16:0e/18:1(9Z))), 1-(1Z-octadecenyl)-2-(9Z-
152	octadecenoyl)-sn-glycero-3-phosphocholine (PC(18:0p/18:1(9Z))), 1-stearoyl-2-hydroxy-sn-
153	glycero-3-phosphocholine (LPC(18:0)), 1-oleoyl-2-hydroxy-sn-glycero-3-phosphocholine
154	(LPC(18:1)), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (PE(16:0/18:1)), 1-(1Z-
155	octadecenyl)-2-docosahexaenoyl-sn-glycero-3-phosphocholine (PC(18:0p/22:6)) and 1-stearoyl-
156	2-linoleoyl-sn-glycerol (DG(18:0/18:2)), 1-(9Z-octadecenoyl)-sn-glycero-3-
157	phosphoethanolamine (LPE(18:1)), N-(9Z-octadecenoyl)-sphinganine (Cer(d18:0/18:1(9Z))), 1-
158	hexadecyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (PE(16:0/18:1)) from Avanti
159	Polar Lipids, 1-Palmitoyl-2-Hydroxy-sn-Glycero-3-Phosphatidylcholine (LPC(16:0)), 1,2,3
160	trihexadecanoalglycerol (TG(16:0/16:0)), 1,2,3-trioctadecanoylglycerol (TG(18:0/18:0/18:))
161	and $3\beta$ -hydroxy-5-cholestene-3-stearate (ChoE(18:0)), $3\beta$ -Hydroxy-5-cholestene-3-linoleate
162	(ChoE(18:2)) from Larodan, were prepared to the following concentration levels: 100, 500, 1000,
163	1500, 2000 and 2500 ng/mL (in CHCl3:MeOH, 2:1, v/v) including 1250 ng/mL of each internal
164	standard.

#### 165 Analysis of polar metabolites

40 µl of serum sample was mixed with 90 µl of cold MeOH/H2O (1:1, v/v) containing the internal 166 standard mixture (Valine-d8, Glutamic acid-d5, Succinic acid-d4, Heptadecanoic acid, Lactic acid-167 d3, Citric acid-d4. 3-Hydroxybutyric acid-d4, Arginine-d7, Tryptophan-d5, Glutamine-d5, each at 168 at c= 1 µgmL-1 and 1-D4-CA,1-D4-CDCA,1-D4-CDCA,1-D4-GCA,1-D4-GCDCA,1-D4-169 GLCA,1-D4-GUDCA,1-D4-LCA,1-D4-TCA, 1-D4-UDCA, each at 0.2 1 µgmL-1) for protein 170 precipitation. The tube was vortexed and ultrasonicated for 3 min, followed by centrifugation 171 (10000 rpm, 5 min). After centrifuging, 90 µl of the upper layer of the solution was transferred to 172 the LC vial and evaporated under the nitrogen gas to the dryness. After drying, the sample was 173 reconstituted into 60 µl of MeOH: H<sub>2</sub>O (70:30). 174

Analyses were performed on an Agilent 1290 Infinity LC system coupled with 6545 QTOFMS 175 interfaced with a dual jet stream electrospray (dual ESI) ion source (Agilent Technologies; Santa 176 Clara, CA, USA) was used for the analysis. Aliquots of 10 µL of samples were injected into the 177 Acquity UPLC BEH C18 2.1 mm × 100 mm, 1.7-µm column (Waters Corporation, Wexford, 178 Ireland), fitted with a C18 precolumn (Waters Corporation, Wexford, Ireland). The mobile phases 179 180 consisted of (A) 2 mM NH<sub>4</sub>Ac in H<sub>2</sub>O: MeOH (7:3) and (B) 2 mM NH<sub>4</sub>Ac in MeOH. The flow rate was set at 0.4 mLmin-1 with the elution gradient as follows: 0-1.5 min, mobile phase B was 181 increased from 5% to 30%; 1.5-4.5 min, mobile phase B increased to 70%; 4.5-7.5 min, mobile 182 183 phase B increased to 100% and held for 5.5 min. A post-time of 5 min was used to regain the initial conditions for the next analysis. The total run time per sample was 20 min. The dual ESI ionization 184 source was settings were as follows: capillary voltage was 4.5 kV, nozzle voltage 1500 V, N2 185 pressure in the nebulized was 21 psi and the N2 flow rate and temperature as sheath gas was 11 186 Lmin-1 and 379 °C, respectively. In order to obtain accurate mass spectra in MS scan, the m/z 187 188 range was set to 100-1700 in negative ion mode. MassHunter B.06.01 software (Agilent Technologies; Santa Clara, CA, USA) was used for all data acquisition. 189

190 MS data processing was performed using same parameters as in lipidomic analysis.

Quantitation was done using 6-point calibration (PFOA c= 3.75-120 ng/mL, bile acids c= 20-640191 ng/mL, polar metabolites c=0.1 to 80  $\mu$ g/mL). Quantification of other bile acids was done using 192 the following compounds: chenodeoxycholic acid (CDCA), cholic acid (CA), deoxycholic acid 193 (DCA), glycochenodeoxycholic acid (GCDCA), glycocholic acid (GCA), glycodehydrocholic 194 195 acid (GDCA), glycodeoxycholic acid (GDCA), glycohyocholic acid (GHCA), glycohyodeoxycholic acid (GHDCA), glycolitocholic acid (GLCA), glycoursodeoxycholic acid 196 (GUDCA), hyocholic acid (HCA), hyodeoxycholic acid (HDCA), litocholic acid (LCA), alpha-197 198 muricholic acid ( $\alpha$ MCA), tauro-alpha-muricholic acid (T- $\alpha$ -MCA), tauro-beta-muricholic acid(Tβ-MCA), taurochenodeoxycholic acid (TCDCA), taurocholic acid (TCA), taurodehydrocholic 199 200 acid (THCA), taurodeoxycholic acid (TDCA), taurohyodeoxycholic acid (THDCA),

taurolitocholic acid (TLCA), tauro-omega-muricholic acid (TωMCA) and tauroursodeoxycholic
acid (TDCA) and polar metabolites was done using alanine, citric acid, fumaric acid, glutamic
acid, glycine, lactic acid, malic acid, 2-hydroxybutyric acid, 3-hydroxybutyric acid, linoleic acid,
oleic acid, palmitic acid, stearic acid, cholesterol, fructose, glutamine, indole-3-propionic acid,
isoleucine, leucine, proline, succinic acid, valine, asparagine, aspartic acid, arachidonic acid,
glycerol-3-phosphate, lysine, methionine, ornithine, phenylalanine, serine and threonine.

207 *QC/QA* 

Quality control was accomplished both for lipidomics, polar metabolites and PFAS analysis by 208 including blanks, pure standard samples, extracted standard samples, pooled quality control 209 samples and standard reference plasma samples (NIST SRM 1950). The pooled sample were 210 prepared by taking an aligout  $(10 \,\mu)$  of each extract, separately for lipidomic and polar metabolite 211 methods, then pooling them, and aliquoting the pool into separate vials. In lipidomic and 212 metabolomic analyses, lipids that had >30% RSD in the pooled QC samples (an equal aliquot of 213 each sample pooled together) or that were present at high concentrations in the extracted blank 214 samples (ratio between samples to blanks < 5) were excluded from the data analyses. 215

#### 216 Statistical analysis

#### 217 Data pre-processing and clustering

In this study, all data analyses were conducted using the R statistical programming language (version 4.1.2) (https://www.r-project.org/). The exposure datasets were pre-processed by log2 transformation and scaling to zero mean and unit variance (auto-scaled). For contaminant exposure analyses, individual contaminant and cluster-level analyses were performed. To cluster the contaminant data, we utilized the '*mclust*' R package (version 5.4.10) for model-based clustering, selecting the model type and the number of clusters based on the highest Bayesian Information Criterion (BIC). To better understand the impact of exposure, we also incorporated lipidomics and

metabolomics data from our previous study (Hyotylainen et al. 2023), which included eight lipid
clusters (LCs) and twelve polar metabolite clusters (PCs), along with their individual features.

#### 227 Demographic data and covariates

In terms of demographic data and covariates, the median age at the time of diagnosis for subjects who later developed autoimmune diseases was 15 years. We obtained information on birthweight, maternal age, gestational age, and BMI from the questionnaire. Additionally, we utilized birthweight and gestational age to calculate birthweight for gestational age (BWGA) Z-score, utilizing internationally validated infant growth charts developed by Fenton (Chou et al. 2020; Fenton and Kim 2013).

#### 234 *Correlation and partial correlation analysis*

Pairwise Spearman's correlation between contaminants, lipid clusters (LCs), Polar metabolite clusters (PCs) and demographic variables (Z-score, Maternal age, BMI) was calculated and visualized using '*corrplot*' R package (version 0.92). Two correlation plots were generated separately for control and cases. The correlation between variables visualised in the form of a matrix plot refers to positive and negative correlations and the strength of the association is referred to by the size of the dot or filled circles.

The Debiased Sparse Partial Correlation algorithm (DSPC) (Basu et al. 2017) was used to estimate partial correlation networks and visualized in the form of a chord diagram using '*circlize*', R package (version 0.4.15) with edge ranges between  $\pm 0.14$  to 1.0 and showing only correlations across contaminants, LCs, PCs and demographic variables.

245 Univariate statistical analysis

To understand the impact of contaminant exposure levels on cord serum metabolome, the subjects were assigned to four quartiles based on the exposure levels. A two-way analysis of variance (ANOVA) test was performed followed by post-hoc Tukey's test by using quartiles (Q1 to Q4)

and subjects (cases and control) as factor variables. ANOVA test helps to identify any significant
changes in the lipid or metabolite clusters and post-hoc Tukey's test helps to identify the specific
quartiles between which significant changes are observed.

252 Regression and classification analysis

253 Predictive logistic ridge regression (LRR) was performed to investigate the impact of individual contaminants on the stratification of autoimmune cases and controls. We have adapted the L2 254 regularization strategy to avoid multicollinearity among highly correlated predictors. Regularized 255 regression modelling was performed using the 'glmnet' package in R (version 4.1-4). The hyper-256 parameter  $\lambda_{\text{minimum}}$  was determined by 10-fold cross-validation using the '*cv.glmnet*' function from 257 'glmnet'. The models were adjusted for Z-score, Maternal age and BMI. The accuracy of 258 prediction was determined by AUCs, where the mean AUC of the model was estimated by 259 bootstrapping, by resampling the exposure dataset into training (80%) and testing (20%) 10,000 260 261 times. All LRR models with a threshold of AUC > 0.60 were considered. Downsampling was performed to address the class imbalance problem (cases, n=62, controls, n > 62). The 'caret' 262 package (version 4.1.3) was used for the partition of data and the best models (based on mean 263 AUCs) were assessed using Receiver Operating Characterisitic (ROC) curves using the 'ROCR' 264 package. Additionally, we have performed a stepwise recursive feature elimination scheme to 265 identify the minimum number of predictors that are needed to maximize the outcome. 266

To investigate the effect of contaminant exposure on the cord blood metabolome, we employed 267 linear regression with L2 regularization (LR), using individual contaminant concentrations as 268 predictors and the concentrations of significantly altered cord blood lipid or polar metabolites (and 269 their cluster) as the response variable. The hyper-parameter  $\lambda_{\text{minimum}}$ , which corresponds to the 270 minimum cross-validation error, was selected through 10-fold cross-validation. We partitioned the 271 data and performed resampling (10,000 iterations) as described earlier. The mean R square was 272 used to estimate the accuracy of prediction and the significant impact of contaminant exposure on 273 the cord blood metabolome. 274

Additionally, we determined the ranks of the predictors using LR and LRR modelling. For the LRR models, the ranks of the predictors were estimated based on the unit absolute differences in the odds ratio, while for the LR models, the ranks were based on the ridge coefficients normalized with the maximum value.

279 Pathway analysis

Pathway enrichment analysis comparing cases versus controls for Deoxynivalenol (DON) impact 280 polar metabolites was performed using the MetaboAnalyst 5.0 web platform with the Functional 281 Analysis (MS Peaks) module (Pang et al. 2022). The input data for the pathway analysis consisted 282 of complete high-resolution LC-MS spectral peak data obtained in negative ionization mode with 283 a mass tolerance of 10 ppm. Linear regression analysis was performed to estimate the association 284 between DON and polar metabolites while adjusting for Z-score, Maternal age, and BMI. The 285 whole input peak list with FDR-corrected p-values and T-score was used for the pathway analysis. 286 Overrepresented pathways were estimated against the background human scale metabolic model 287 MNF (from MetaboAnalyst Mummichog package) and Kyoto Encyclopedia of Genes and 288 Genomes (KEGG) pathways for Homo sapiens to determine the relative significance of the 289 identified pathways (Li et al. 2020). The MetaboAnalyst 5.0 metabolomics pathway analysis 290 (MetPA) tool(Xia and Wishart 2010) was used to calculate the Pathway Impact Scores (Chong et 291 al. 2018; Pang et al. 2022). 292

## 293 **Results**

#### 294 Metabolomic analysis of the cord blood

Fig. 1 summarizes the integration of exposomics and metabolomics workflows in the ABIS cohort. Cord serum samples were analyzed for a total of 545 lipids and 3417 polar metabolites, which were further grouped into 8 lipid clusters and 12 polar metabolite clusters, respectively. We previously found significant associations between the metabolite clusters and demographic

variables or clinical parameters such as gestational age, maternal age, and birth weight (Hyotylainen et al. 2023). To account for these associations, we used the Z-score as calculated from birth weight, gestational age, and maternal BMI as covariates in our analysis.

#### 302 Levels of contaminants in the cord blood

303 A total of 20 contaminants, including several PFAS compounds, were detected in cord blood samples from both control and case groups (Table S1). Differences (p<0.05) in concentration 304 levels between control and case groups were observed for Perfluorooctanoic acid Branched 2, 305 Environmental Contaminant 1, Perfluorooctanoic acid Linear 1, Perfluorooctanoic acid Linear 2 306 and Methylparaben (Fig. 2). At the individual disease level, Environmental Contaminant 1, 307 Perfluorooctanoic acid Linear 2 and Perfluorooctanoic acid Branched 2 showed differences 308 (p<0.05) in concentration levels between control and individual disease groups (**Fig. S1**). The 309 contaminants were reduced to four clusters (CC1-CC4) consisting of eight contaminants, including 310 Bisphenol S, Deoxynivalenol, Monobutyl phthalate, and a-Zearalanol in CC1; Ethylparaben, 311 Methylparaben, and Propylparaben in CC2; Perfluorohexanesulfonic acid (PFHxS) and 312 Perfluorohexanesulfonic acid Branched (PFHxSBr) in CC3; and seven PFAS and their fragments 313 as part of CC4 (Table S1). 314

#### 315 Exposure level of contaminants as a predictor for immune-mediated diseases

We employed predictive logistic ridge regression (LRR) models to stratify controls and cases based on their contaminant concentrations. The models were fitted using all predictors or by using the stepwise recursive feature elimination (RFE) method. The mean area under the curve (AUC) values for the models were 0.65 (95% CI 0.63-0.67) when using all predictors and 0.67 (95% CI 0.66-0.68) when using the stepwise RFE method (**Fig. S2**). Our results showed that the contaminant concentration levels have a modest potential to differentiate controls from autoimmune diseases, as indicated by the mean AUC values (**Fig. S2**). The ranks of individual

contaminants (predictors) for separating controls and cases were estimated based on the unit
 absolute difference in odds ratios (Fig. S2A).

#### 325 Associations between contaminants and cord serum metabolic profiles

We found significant associations between contaminants and cord serum metabolic profiles (Fig. 326 327 3). Specifically, more associations were observed between PFAS exposures and metabolic profiles in cases than in controls. Maternal age was positively associated with metabolite cluster PC1 in 328 cases but not in controls (Fig. 3). We also performed partial correlation network analysis to identify 329 non-spurious associations and Fig. 4 shows the marked associations between contaminants and 330 cord serum metabolic profiles along with demographic variables. In the case group (Fig. 4B), the 331 covariates Z-score, maternal age, and BMI showed a stronger association with exposure and cord 332 serum metabolic profiles compared to the control group (Fig. 4A). The mycotoxins including 333 deoxynivalenol were found to be associated with PC2 (phosphatidylcholines) and PC10 334 335 (unknowns), while a-zearalanol was associated with PC1 (lysophosphatidylcholines, sphingomyelins, and ceramides) (Fig. 4). 336

# Impact of contaminant exposure on cord serum metabolites associated with immune mediated diseases

The samples were stratified into quartiles based on their level of exposure to contaminants, and 339 340 the impact of exposure on metabolite levels was assessed at both individual contaminant levels and cluster levels (CC1-CC4) (Tables S2-S5). The polar metabolite clusters displayed more 341 significant mean differences between the highest (Q4) and lowest (Q1) quartiles, as shown in 342 Table S4-S5. In CC1, significant mean differences between Q4 and Q1 were observed for LC3, 343 LC4, and LC7 at the lipid cluster level (Table S3). In CC3, which includes 344 perfluorohexanesulfonic acid (PFHxS) and branched (PFHxSBr), significant mean differences 345 between the highest and lowest quartiles were observed for LC5 and LC6 (Table S3 and Fig. 5H). 346

Linear ridge regression (LR) was performed to determine the quantitative effect of contaminant 347 concentration levels on cord serum metabolic profiles. The results showed that polar metabolites 348 in cord serum were more highly impacted by contaminant exposure than lipid levels. Specifically, 349 six polar metabolite clusters, PC2 ( $R^2 = 0.72$ ), PC6 ( $R^2 = 0.53$ ), PC4 ( $R^2 = 0.52$ ), PC1 ( $R^2 = 0.48$ ), 350 PC10 ( $R^2 = 0.48$ ), and PC11 ( $R^2 = 0.32$ ), showed significant associations with exposure levels 351 (Fig. 5 and Fig. S3). At the individual metabolite level, amino acids such as tryptophan (Fig. 5C), 352 Serine of PC2, and 3-Chlorothieno [2,3-b]thiophene-2-carbonyl chloride of PC11 showed a 353 significant impact (Fig. 5F). According to the ranks of the predictors (contaminants), 354 355 deoxynivalenol (DON) and Bisphenol S were the top linear predictors of cord serum metabolites and clusters PC2 and PC11 (Fig. 5A-F). 356

Although the contaminants from clusters CC1 and CC3 showed a significant association between quartiles (Q4 vs. Q1) and lipid cluster levels LC3, LC4, LC5, LC6, and LC7, their strength of association based on LR models was comparatively weaker (**Fig. 5G-I** and **Fig. S3**). For example, the lipid cluster LC6, which mainly comprises triglycerides containing monounsaturated fatty acid (MUFA) and polyunsaturated fatty acids (PUFA), showed a weaker association ( $R^2 = 0.04$ ) with contaminant exposures (**Fig. 5G-I**).

#### 363 Pathway analysis of deoxynivalenol exposure

Metabolic pathway enrichment analysis was performed to evaluate the impact of DON on polar metabolites in both control and case groups separately. DON was found to be the top predictor that impacted polar metabolite clusters PC2, PC4, PC10, and PC11, as shown in **Fig. 5** and **Fig. S3**. Both Mummichog and GeneSet Enrichment Analysis (GSEA) algorithms were utilized using MetaboAnalyst 5.0 (Li et al. 2020; Pang et al. 2022). Based on the pathways identified by the impact of DON exposure, both control and case groups showed common and specific metabolic pathways, as presented in **Tables S6-S9**.

The MFN pathway map revealed that DON exposure was associated with 'Tyrosine and 371 Tryptophan metabolism' in the control group but not in cases. Also 'Glutathione Metabolism', 372 373 'Alanine and Aspartate Metabolism', and 'Glycerophospholipid metabolism' were found to be associated with exposure to DON in cases, but not in controls (Fig. 6A and 6C; Tables S6 and 374 **S8**). Similarly, based on the KEGG pathway maps, 'Aminoacyl-tRNA biosynthesis' and 'Glycine, 375 376 serine, and threonine metabolism' were common among control and case groups, while several other metabolic pathways were specific to each group (Fig. 6B and 6D, Tables S7 and S9). In 377 summary, the pathway enrichment analysis provided insights into the metabolic pathways affected 378 379 by DON exposure in both control and case groups. The results highlight the differences in the impacted pathways between the two groups based on the exposure to DON. 380

## 381 **Discussion**

We performed integrated exposomics and metabolomics to detect the levels of exposure to 382 contaminants and metabolite levels in cord serum. This comprehensive approach allowed us to 383 assess the combined impact of environmental exposures and metabolic profiles on autoimmune 384 385 diseases in the ABIS cohort. In our previous study we found similarities in metabolic profiles across different autoimmune diseases at birth (Hyotylainen et al. 2023). In order to avoid class 386 imbalance problems, here we pooled all individual diseases together. We detected 20 387 contaminants, encompassing several PFAS compounds, Bisphenol S, and mycotoxins like 388 Deoxynivalenol (DON), in cord blood samples from both control and case groups. Previous 389 studies, including our own, have reported detectable levels of PFAS compounds (McGlinchey et 390 al. 2020; Sinisalu et al. 2020), Bisphenol S exposure (Liu et al. 2017), and the presence of 391 mycotoxins, including Deoxynivalenol (DON), in cord blood samples (Nielsen et al. 2011). These 392 393 findings provide a backdrop for our investigation into the associations between these contaminants and autoimmune diseases in the ABIS cohort. We were able to demonstrate significant differences 394 in the exposure levels of certain contaminants, such as Perfluorooctanoic acid Branched 2, 395 396 Environmental Contaminant 1, Perfluorooctanoic acid Linear 1, Perfluorooctanoic acid Linear 2,

and Methylparaben, in cord blood between the control and case groups. However, it is important 397 398 to note that while these differences were statistically significant, the effect sizes were relatively modest. This suggests that while contaminants do play a role in distinguishing between controls 399 and autoimmune diseases, they are unlikely to be the sole risk factors. Various factors including 400 genetics, environmental triggers, and lifestyle factors, and their mutual interactions, contribute to 401 402 the development of autoimmune diseases (Ellis et al. 2014; Oresic et al. 2013; Oresic et al. 2008; Rewers and Ludvigsson 2016; Sen et al. 2019; Sen et al. 2020; Sinisalu et al. 2020; Vermeulen et 403 al. 2020; Virolainen et al. 2023). 404

Our study revealed differences in exposure and metabolite profiles between individuals who later 405 developed autoimmune diseases and controls, particularly in relation to Z-score, mothers' age, and 406 407 BMI. This suggests that there may be differences in maternal factors between the two groups even at birth. We also observed that high levels of exposure to environmental contaminants were 408 associated with changes in amino acid and free fatty acid profiles in the cord blood metabolome. 409 Although we previously found a significant impact on lipid profiles, particularly triacylglycerols, 410 the strength of association is weaker compared to the effect on polar metabolites (Hyotylainen et 411 412 al. 2023). Among the 20 contaminants measured in our study, DON, Bisphenol S, and some branched PFAS compounds are the primary predictors of changes in cord serum metabolic 413 profiles. While the associations between PFAS exposure and their marked effect on metabolism 414 415 leading to autoimmune diseases have been well documented in previous studies (Ehrlich et al. 2023; McGlinchey et al. 2020; Rudzanova et al. 2023; Sinisalu et al. 2020), the exposure to DON 416 and BPS and their impact on autoimmune diseases is less studied. 417

While our study detected Bisphenol S (BPS) and not Bisphenol A (BPA), it's noteworthy that BPA, a common chemical found in plastics, has been associated with alterations in amino acid metabolism (Wang et al. 2018). BPA has been linked to changes in phenylalanine, tryptophan, tyrosine, lysine, and arginine metabolism, with a particular impact on female infants (Khan et al. 2017). In the case of BPS, it was shown to have sex- and diet-dependent effects on the development

423 of type 1 diabetes (T1D) in non-obese diabetic (NOD) mice. Female mice exposed to BPS on a 424 soy-based diet exhibited delayed T1D development, while males showed increased insulin 425 resistance (Xu et al. 2019). These findings suggest that both BPA and BPS can influence 426 metabolism and immune responses, potentially contributing to autoimmune diseases like T1D, 427 although there is less evidence regarding the effect of BPS in humans.

Deoxynivalenol (DON) exposure in pregnant women has been reported in various studies. In the UK, pregnant women from diverse backgrounds showed detectable urinary DON levels, with South Asian women having higher exposure, primarily from bread consumption (Hepworth et al. 2012). Similarly, in Norway, DON, a common mycotoxin in cereals, was found in various cerealbased foods, potentially affecting the immune system, particularly in infants and young children (Sundheim et al. 2017). In pregnant Egyptian women, DON co-occurred with other mycotoxins, raising concerns about maternal and fetal health (Piekkola et al. 2012).

These findings emphasize the importance of assessing DON exposure in pregnant women and its potential health implications. DON exposure, prevalent in grains, adversely affects the immune system in both humans and animals and has been linked to alterations in gut microbiota (Liao et al. 2018). This immunotoxicity induced by DON involves mechanisms such as MAPK activation, ER stress, and mitochondrial signaling pathways (Liao et al. 2018).

440 To delve deeper into the potential mechanisms underlying these associations, we conducted pathway analysis of DON exposure on polar metabolites within both control and case groups. This 441 analysis revealed that DON had distinct impacts on metabolic pathways in these groups. In the 442 control group, DON exposure was associated with alterations in 'Tyrosine and Tryptophan 443 metabolism,' indicating potential effects on amino acid pathways. Conversely, the case group 444 showed associations between DON exposure and 'Glutathione Metabolism,' 'Alanine and 445 Aspartate Metabolism,' and 'Glycerophospholipid metabolism,' suggesting disruptions in 446 antioxidant defense systems and lipid metabolism. These findings align with previous research 447 448 indicating that DON can induce oxidative stress by reducing antioxidant enzyme activity and

enhancing lipid peroxidation (Mishra et al. 2014). The marked association between DON and 449 phosphatidylcholines in our study suggests a potential link between mycotoxin exposure and 450 451 alterations in lipid metabolism, particularly in the context of phosphatidylcholines. This finding is noteworthy, as specific phosphatidylcholines were previously identified as persistently down-452 regulated in children who later progressed to islet autoimmunity (Johnson et al. 2019) and clinical 453 454 type 1 diabetes (T1D) (Oresic et al. 2008). Thus, the oxidative stress response and its impact on lipid metabolism, triggered by DON exposure, may play a pivotal role in the pathogenesis of 455 autoimmune diseases, warranting further investigation. 456

These differential effects of DON exposure on metabolic pathways between control and case 457 groups highlight the intricate relationship between environmental exposures, metabolism, and 458 459 immune dysregulation in the context of autoimmune diseases. While our study contributes to our understanding of the metabolic consequences of DON exposure, it's essential to consider these 460 findings within the broader context of various factors, including genetics, environmental triggers, 461 and lifestyle factors, which collectively contribute to the development of autoimmune diseases. 462 Understanding these effects is crucial when assessing DON exposure during pregnancy and its 463 464 potential health consequences. In this study, the median age of diagnosis of autoimmune diseases was higher compared to previous studies in genetically high-risk cohorts (Oresic et al. 2013; Oresic 465 et al. 2008; Sen et al. 2019). Despite some common metabolic patterns (Hyotylainen et al. 2023), 466 there were differences and limitations to consider. One important limitation of our study was the 467 small sample size within each disease group, which restricted our analysis. Another limitation of 468 our study was the lack of maternal exposure and longitudinal exposure data at different time points 469 between birth and the onset of autoimmune diseases, which could explain their age-dependent 470 progression. 471

Our previous studies in T1D (McGlinchey et al. 2020) and CD (Sinisalu et al. 2020) cohorts have mainly focus on the associations of PFAS exposure with the disease risk. Here we detected the levels of other contaminants such as Bisphenol S and some mycotoxins including DON and a-

Zearalanol, which potentially show the differences in exposures. Mycotoxins are common contaminants of cereals and grains, and exposure to them is also associated with autoimmune disorders (Gayathri et al. 2018; Kraft et al. 2021; Liao et al. 2018; Rotter et al. 1996). This emphasizes the need for caution and control over mycotoxin exposure, particularly during pregnancy and critical developmental stages.

Altogether, our results show that high prenatal exposure to environmental contaminants associated with altered cord serum metabolite levels and may result in the progression of autoimmune diseases in the ABIS cohort. Other factors such as Z-score, maternal age and BMI are associated with contaminant exposure levels. Mechanistic studies are required to elucidate pathways of disease progression upon exposure.

#### 485 Author contributions

Bagavathy Shanmugam Karthikeyan: Formal analysis, Software, Visualization, Writing - Original
Draft; Tuulia Hyötyläinen: Conceptualization, methodology, formal analysis, investigation,
writing – original draft, supervision, project administration, funding acquisition; Tannaz
Ghaffarzadegan: Writing – review and editing, methodology; Eric W. Triplett: Conceptualization,
writing – review and editing; Matej Orešič: Conceptualization, writing – original draft, formal
analysis, supervision; Johnny Ludvigsson: Conceptualization, writing – review and editing,
funding acquisition, design and management of the ABIS cohort study.

## 493 Acknowledgements

BSK thanks Partho Sen for his guidance in Methods and Alex Dickens for his insightful discussions. The authors thank Dirk Repsilber for his support in using the UCS-1 server from Örebro University for computations. This work was supported by the Swedish Research Council [grant number 2020-03674; to TH], Formas [grant number 2019-00869; to TH], and by the "Inflammation in human early life: targeting impacts on life-course health" (INITIALISE)

499	consortium funded by the Horizon Europe Program of the European Union under Grant Agreement
500	101094099 (to T.H., E.W.T., M.O., and J.L. ). The ABIS cohort study (JL) was supported by
501	Barndiabetesfonden (Swedish Child Diabetes Foundation), the Swedish Council for Working Life
502	and Social Research [grant numbers FAS2004-1775 and FAS2004-1775], Swedish Research
503	Council [Grant/Award Numbers: K2005-72 × -11242-11A and K2008-69 × -20826-01-4, K2008-
504	69×-20826-01-4], Östgöta Brandstodsbolag, Medical Research Council of Southeast Sweden
505	(FORSS), JDRF Wallenberg Foundation [Grant/Award Number: K 98-99D-12813-01A], Joanna
506	Cocozza Foundation and ALF-and LfoU grants from Region Östergötland and Linköping
507	University, Sweden.

## 508 **Competing interests**

509 The authors have no competing interests to declare.

## 510 Data accessibility

- 511 Data are available upon reasonable request after ethical approvement and an appropriate
- institutional collaboration agreement. These data are not available to access in a repository owing
- to concern that the identity of patients might be revealed inadvertently.

## 514 **References**

- Basu, S.; Duren, W.; Evans, C.R.; Burant, C.F.; Michailidis, G.; Karnovsky, A. Sparse network
   modeling and metscape-based visualization methods for the analysis of large-scale
   metabolomics data. Bioinformatics 2017;33:1545-1553
- Belteky, M.; Milletich, P.L.; Ahrens, A.P.; Triplett, E.W.; Ludvigsson, J. Infant gut microbiome
   composition correlated with type 1 diabetes acquisition in the general population: the
   ABIS study. Diabetologia 2023;66:1116-1128
- Berhan, Y.; Waernbaum, I.; Lind, T.; Mollsten, A.; Dahlquist, G.; Swedish Childhood Diabetes
   Study, G. Thirty years of prospective nationwide incidence of childhood type 1 diabetes:
   the accelerating increase by time tends to level off in Sweden. Diabetes 2011;60:577-581
- Buhimschi, I.A.; Buhimschi, C.S. Proteomics/diagnosis of chorioamnionitis and of relationships
   with the fetal exposome. Semin Fetal Neonatal Med 2012;17:36-45
- Carstensen, B.; Ronn, P.F.; Jorgensen, M.E. Prevalence, incidence and mortality of type 1 and
   type 2 diabetes in Denmark 1996-2016. BMJ Open Diabetes Res Care 2020;8

529	<ul> <li>Chew, N.W.S.; Ng, C.H.; Tan, D.J.H.; Kong, G.; Lin, C.; Chin, Y.H.; Lim, W.H.; Huang, D.Q.;</li></ul>
530	Quek, J.; Fu, C.E.; Xiao, J.; Syn, N.; Foo, R.; Khoo, C.M.; Wang, J.W.; Dimitriadis,
531	G.K.; Young, D.Y.; Siddiqui, M.S.; Lam, C.S.P.; Wang, Y.; Figtree, G.A.; Chan, M.Y.;
532	Cummings, D.E.; Noureddin, M.; Wong, V.W.; Ma, R.C.W.; Mantzoros, C.S.; Sanyal,
533	A.; Muthiah, M.D. The global burden of metabolic disease: Data from 2000 to 2019. Cell
534	Metab 2023;35:414-428 e413
535	Chong, J.; Soufan, O.; Li, C.; Caraus, I.; Li, S.; Bourque, G.; Wishart, D.S.; Xia, J.
536	MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis.
537	Nucleic Acids Res 2018;46:W486-W494
538	Chou, J.H.; Roumiantsev, S.; Singh, R. PediTools Electronic Growth Chart Calculators:
539	Applications in Clinical Care, Research, and Quality Improvement. J Med Internet Res
540	2020;22:e16204
541	Cui, Y.; Balshaw, D.M.; Kwok, R.K.; Thompson, C.L.; Collman, G.W.; Birnbaum, L.S. The
542	Exposome: Embracing the Complexity for Discovery in Environmental Health. Environ
543	Health Perspect 2016;124:A137-140
544 545 546	Diseases, G.B.D.; Injuries, C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1204-1222
547 548	Eaton, W.W.; Rose, N.R.; Kalaydjian, A.; Pedersen, M.G.; Mortensen, P.B. Epidemiology of autoimmune diseases in Denmark. J Autoimmun 2007;29:1-9
549	Ehrlich, V.; Bil, W.; Vandebriel, R.; Granum, B.; Luijten, M.; Lindeman, B.; Grandjean, P.;
550	Kaiser, A.M.; Hauzenberger, I.; Hartmann, C.; Gundacker, C.; Uhl, M. Consideration of
551	pathways for immunotoxicity of per- and polyfluoroalkyl substances (PFAS). Environ
552	Health 2023;22:19
553	Ellis, J.A.; Kemp, A.S.; Ponsonby, A.L. Gene-environment interaction in autoimmune disease.
554	Expert Rev Mol Med 2014;16:e4
555 556	Fenton, T.R.; Kim, J.H. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr 2013;13:59
557	Filimoniuk, A.; Daniluk, U.; Samczuk, P.; Wasilewska, N.; Jakimiec, P.; Kucharska, M.;
558	Lebensztejn, D.M.; Ciborowski, M. Metabolomic profiling in children with inflammatory
559	bowel disease. Adv Med Sci 2020;65:65-70
560	Gayathri, L.; Karthikeyan, B.S.; Rajalakshmi, M.; Dhanasekaran, D.; Li, A.P.; Akbarsha, M.A.
561	Metabolism-dependent cytotoxicity of citrinin and ochratoxin A alone and in
562	combination as assessed adopting integrated discrete multiple organ co-culture (IdMOC).
563	Toxicol In Vitro 2018;46:166-177
564 565	Harjutsalo, V.; Sund, R.; Knip, M.; Groop, P.H. Incidence of type 1 diabetes in Finland. JAMA 2013;310:427-428
566	Hepworth, S.J.; Hardie, L.J.; Fraser, L.K.; Burley, V.J.; Mijal, R.S.; Wild, C.P.; Azad, R.;
567	McKinney, P.A.; Turner, P.C. Deoxynivalenol exposure assessment in a cohort of
568	pregnant women from Bradford, UK. Food Addit Contam Part A Chem Anal Control
569	Expo Risk Assess 2012;29:269-276

570 571	Hyotylainen, T.; Karthikeyan, B.S.; Ghaffarzadegan, T.; Triplett, E.W.; Oresic, M.; Ludvigsson, J. Cord serum metabolic signatures of future progression to immune-mediated diseases.
572	iScience 2023;26:106268
573	Ilonen, J.; Kiviniemi, M.; Lempainen, J.; Simell, O.; Toppari, J.; Veijola, R.; Knip, M.; Finnish
574	Pediatric Diabetes, R. Genetic susceptibility to type 1 diabetes in childhood - estimation
575	of HLA class II associated disease risk and class II effect in various phases of islet
576	autoimmunity. Pediatr Diabetes 2016;17 Suppl 22:8-16
577	Johnson, R.K.; Tamura, R.; Frank, N.; Uusitalo, U.; Yang, J.; Niinisto, S.; Andren Aronsson, C.;
578	Ziegler, A.G.; Hagopian, W.; Rewers, M.; Toppari, J.; Akolkar, B.; Krischer, J.;
579	Virtanen, S.M.; Norris, J.M.; Group, T.S. Maternal food consumption during late
580	pregnancy and offspring risk of islet autoimmunity and type 1 diabetes. Diabetologia
581	2021;64:1604-1612
582	Johnson, R.K.; Vanderlinden, L.; DeFelice, B.C.; Kechris, K.; Uusitalo, U.; Fiehn, O.; Sontag,
583	M.; Crume, T.; Beyerlein, A.; Lernmark, A.; Toppari, J.; Ziegler, A.G.; She, J.X.;
584	Hagopian, W.; Rewers, M.; Akolkar, B.; Krischer, J.; Virtanen, S.M.; Norris, J.M.;
585	Group, T.S. Metabolite-related dietary patterns and the development of islet
586	autoimmunity. Sci Rep 2019;9:14819
587	Karthikeyan, B.S.; Ravichandran, J.; Aparna, S.R.; Samal, A. ExHuMId: A curated resource and
588	analysis of Exposome of Human Milk across India. Chemosphere 2021;271:129583
589	Katsarou, A.; Gudbjornsdottir, S.; Rawshani, A.; Dabelea, D.; Bonifacio, E.; Anderson, B.J.;
590	Jacobsen, L.M.; Schatz, D.A.; Lernmark, A. Type 1 diabetes mellitus. Nat Rev Dis
591	Primers 2017;3:17016
592	Khan, A.; Park, H.; Lee, H.A.; Park, B.; Gwak, H.S.; Lee, H.R.; Jee, S.H.; Park, Y.H. Elevated
593	Metabolites of Steroidogenesis and Amino Acid Metabolism in Preadolescent Female
594	Children With High Urinary Bisphenol A Levels: A High-Resolution Metabolomics
595	Study. Toxicol Sci 2017;160:371-385
596	Khan, M.F.; Wang, H. Environmental Exposures and Autoimmune Diseases: Contribution of
597	Gut Microbiome. Front Immunol 2019;10:3094
598	Kindgren, E.; Ahrens, A.P.; Triplett, E.W.; Ludvigsson, J. Infant gut microbiota and
599	environment associate with juvenile idiopathic arthritis many years prior to disease onset,
600	especially in genetically vulnerable children. EBioMedicine 2023;93:104654
601	Kostic, A.D.; Gevers, D.; Siljander, H.; Vatanen, T.; Hyotylainen, T.; Hamalainen, A.M.; Peet,
602	A.; Tillmann, V.; Poho, P.; Mattila, I.; Lahdesmaki, H.; Franzosa, E.A.; Vaarala, O.; de
603	Goffau, M.; Harmsen, H.; Ilonen, J.; Virtanen, S.M.; Clish, C.B.; Oresic, M.;
604	Huttenhower, C.; Knip, M.; Group, D.S.; Xavier, R.J. The dynamics of the human infant
605	gut microbiome in development and in progression toward type 1 diabetes. Cell Host
606	Where 2013,17.200-275
607	Kraft, S.; Buchenauer, L.; Polte, T. Mold, Mycotoxins and a Dysregulated Immune System: A
800	Combination of Concern? Int J Wol Sci 2021;22
609	Landrigan, P.J.; Goldman, L.R. Children's vulnerability to toxic chemicals: a challenge and
611 010	opportunity to strengthen health and environmental policy. Health All (Millwood) 2011-30-842-850
011	2011,JU.0+2-0JU

medRxiv preprint doi: https://doi.org/10.1101/2023.11.10.23298353; this version posted November 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

	perpetuity.	
It is made available under a	CC-BY-NC-ND 4.0 International license	

612	Landrigan, P.J.; Sly, J.L.; Ruchirawat, M.; Silva, E.R.; Huo, X.; Diaz-Barriga, F.; Zar, H.J.;
613	King, M.; Ha, E.H.; Asante, K.A.; Ahanchian, H.; Sly, P.D. Health Consequences of
614	Environmental Exposures: Changing Global Patterns of Exposure and Disease. Ann Glob
615	Health 2016;82:10-19
616 617 618	Li, S.; Cirillo, P.; Hu, X.; Tran, V.; Krigbaum, N.; Yu, S.; Jones, D.P.; Cohn, B. Understanding mixed environmental exposures using metabolomics via a hierarchical community network model in a cohort of California women in 1960's. Reprod Toxicol 2020;92:57-65
619 620	Liao, Y.; Peng, Z.; Chen, L.; Nussler, A.K.; Liu, L.; Yang, W. Deoxynivalenol, gut microbiota and immunotoxicity: A potential approach? Food Chem Toxicol 2018;112:342-354
621	Liu, J.; Li, J.; Wu, Y.; Zhao, Y.; Luo, F.; Li, S.; Yang, L.; Moez, E.K.; Dinu, I.; Martin, J.W.
622	Bisphenol A Metabolites and Bisphenol S in Paired Maternal and Cord Serum. Environ
623	Sci Technol 2017;51:2456-2463
624 625	Ludvigsson, J.; Ludvigsson, M.; Sepa, A. Screening for prediabetes in the general child population: maternal attitude to participation. Pediatr Diabetes 2001;2:170-174
626 627 628 629 630	<ul> <li>McGlinchey, A.; Sinioja, T.; Lamichhane, S.; Sen, P.; Bodin, J.; Siljander, H.; Dickens, A.M.; Geng, D.; Carlsson, C.; Duberg, D.; Ilonen, J.; Virtanen, S.M.; Dirven, H.; Berntsen, H.F.; Zimmer, K.; Nygaard, U.C.; Oresic, M.; Knip, M.; Hyotylainen, T. Prenatal exposure to perfluoroalkyl substances modulates neonatal serum phospholipids, increasing risk of type 1 diabetes. Environ Int 2020;143:105935</li> </ul>
631 632	Mishra, S.; Dwivedi, P.D.; Pandey, H.P.; Das, M. Role of oxidative stress in Deoxynivalenol induced toxicity. Food Chem Toxicol 2014;72:20-29
633 634	Nielsen, J.K.; Vikstrom, A.C.; Turner, P.; Knudsen, L.E. Deoxynivalenol transport across the human placental barrier. Food Chem Toxicol 2011;49:2046-2052
635	Nygren, M.; Carstensen, J.; Koch, F.; Ludvigsson, J.; Frostell, A. Experience of a serious life
636	event increases the risk for childhood type 1 diabetes: the ABIS population-based
637	prospective cohort study. Diabetologia 2015;58:1188-1197
638	Oresic, M.; Gopalacharyulu, P.; Mykkanen, J.; Lietzen, N.; Makinen, M.; Nygren, H.; Simell, S.;
639	Simell, V.; Hyoty, H.; Veijola, R.; Ilonen, J.; Sysi-Aho, M.; Knip, M.; Hyotylainen, T.;
640	Simell, O. Cord serum lipidome in prediction of islet autoimmunity and type 1 diabetes.
641	Diabetes 2013;62:3268-3274
642	Oresic, M.; Simell, S.; Sysi-Aho, M.; Nanto-Salonen, K.; Seppanen-Laakso, T.; Parikka, V.;
643	Katajamaa, M.; Hekkala, A.; Mattila, I.; Keskinen, P.; Yetukuri, L.; Reinikainen, A.;
644	Lahde, J.; Suortti, T.; Hakalax, J.; Simell, T.; Hyoty, H.; Veijola, R.; Ilonen, J.;
645	Lahesmaa, R.; Knip, M.; Simell, O. Dysregulation of lipid and amino acid metabolism
646	precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med
647	2008;205:2975-2984
648	Pang, Z.; Zhou, G.; Ewald, J.; Chang, L.; Hacariz, O.; Basu, N.; Xia, J. Using MetaboAnalyst 5.0
649	for LC-HRMS spectra processing, multi-omics integration and covariate adjustment of
650	global metabolomics data. Nat Protoc 2022;17:1735-1761
651	Patterson, C.C.; Dahlquist, G.G.; Gyurus, E.; Green, A.; Soltesz, G.; Group, E.S. Incidence
652	trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases
653	2005-20: a multicentre prospective registration study. Lancet 2009;373:2027-2033

medRxiv preprint doi: https://doi.org/10.1101/2023.11.10.23298353; this version posted November 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

	perpetuity.
It is made available under a	CC-BY-NC-ND 4.0 International license

654	Piekkola, S.; Turner, P.C.; Abdel-Hamid, M.; Ezzat, S.; El-Daly, M.; El-Kafrawy, S.;			
655	Savchenko, E.; Poussa, T.; Woo, J.C.; Mykkanen, H.; El-Nezami, H. Characterisation of			
656	aflatoxin and deoxynivalenol exposure among pregnant Egyptian women. Food Addit			
657	Contam Part A Chem Anal Control Expo Risk Assess 2012;29:962-971			
658	Pluskal, T.; Castillo, S.; Villar-Briones, A.; Oresic, M. MZmine 2: modular framework for			
659	processing, visualizing, and analyzing mass spectrometry-based molecular profile data.			
660	BMC Bioinformatics 2010;11:395			
661 662	Rewers, M.; Ludvigsson, J. Environmental risk factors for type 1 diabetes. Lancet 2016;387:2340-2348			
663	Robinson, O.; Vrijheid, M. The Pregnancy Exposome. Curr Environ Health Rep 2015;2:204-213			
664 665	Rosenblum, M.D.; Gratz, I.K.; Paw, J.S.; Abbas, A.K. Treating human autoimmunity: current practice and future prospects. Sci Transl Med 2012;4:125sr121			
666 667	Rotter, B.A.; Prelusky, D.B.; Pestka, J.J. Toxicology of deoxynivalenol (vomitoxin). J Toxicol Environ Health 1996;48:1-34			
668	Rudzanova, B.; Vlaanderen, J.; Kalina, J.; Piler, P.; Zvonar, M.; Klanova, J.; Blaha, L.;			
669	Adamovsky, O. Impact of PFAS exposure on prevalence of immune-mediated diseases in			
670	adults in the Czech Republic. Environ Res 2023;229:115969			
671	Sen, P.; Carlsson, C.; Virtanen, S.M.; Simell, S.; Hyoty, H.; Ilonen, J.; Toppari, J.; Veijola, R.;			
672	Hyotylainen, T.; Knip, M.; Oresic, M. Persistent Alterations in Plasma Lipid Profiles			
673	Before Introduction of Gluten in the Diet Associated With Progression to Celiac Disease.			
674	Clin Transl Gastroenterol 2019;10:1-10			
675	Sen, P.; Dickens, A.M.; Lopez-Bascon, M.A.; Lindeman, T.; Kemppainen, E.; Lamichhane, S.;			
676	Ronkko, T.; Ilonen, J.; Toppari, J.; Veijola, R.; Hyoty, H.; Hyotylainen, T.; Knip, M.;			
677	Oresic, M. Metabolic alterations in immune cells associate with progression to type 1			
678	diabetes. Diabetologia 2020;63:1017-1031			
679 680 681 682 683 684	<ul> <li>Shaffer, R.M.; Sellers, S.P.; Baker, M.G.; de Buen Kalman, R.; Frostad, J.; Suter, M.K.;</li> <li>Anenberg, S.C.; Balbus, J.; Basu, N.; Bellinger, D.C.; Birnbaum, L.; Brauer, M.; Cohen,</li> <li>A.; Ebi, K.L.; Fuller, R.; Grandjean, P.; Hess, J.J.; Kogevinas, M.; Kumar, P.; Landrigan,</li> <li>P.J.; Lanphear, B.; London, S.J.; Rooney, A.A.; Stanaway, J.D.; Trasande, L.; Walker,</li> <li>K.; Hu, H. Improving and Expanding Estimates of the Global Burden of Disease Due to</li> <li>Environmental Health Risk Factors. Environ Health Perspect 2019;127:105001</li> </ul>			
685	Sinisalu, L.; Sen, P.; Salihovic, S.; Virtanen, S.M.; Hyoty, H.; Ilonen, J.; Toppari, J.; Veijola, R.;			
686	Oresic, M.; Knip, M.; Hyotylainen, T. Early-life exposure to perfluorinated alkyl			
687	substances modulates lipid metabolism in progression to celiac disease. Environ Res			
688	2020;188:109864			
689	Sundheim, L.; Lillegaard, I.T.; Faeste, C.K.; Brantsaeter, A.L.; Brodal, G.; Eriksen, G.S.			
690	Deoxynivalenol Exposure in Norway, Risk Assessments for Different Human Age			
691	Groups. Toxins (Basel) 2017;9			
692 693	Tincani, A.; Dall'Ara, F.; Lazzaroni, M.G.; Reggia, R.; Andreoli, L. Pregnancy in patients with autoimmune disease: A reality in 2016. Autoimmun Rev 2016;15:975-977			
694	Vatanen, T.; Franzosa, E.A.; Schwager, R.; Tripathi, S.; Arthur, T.D.; Vehik, K.; Lernmark, A.;			
695	Hagopian, W.A.; Rewers, M.J.; She, J.X.; Toppari, J.; Ziegler, A.G.; Akolkar, B.;			

medRxiv preprint doi: https://doi.org/10.1101/2023.11.10.23298353; this version posted November 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .	

Krischer, J.P.; Stewart, C.J.; Ajami, N.J.; Petrosino, J.F.; Gevers, D.; Lahdesmaki, H.; Vlamakis, H.; Huttenhower, C.; Xavier, R.J. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. Nature 2018;562:589-594
Vermeulen, R.; Schymanski, E.L.; Barabasi, A.L.; Miller, G.W. The exposome and health: Where chemistry meets biology. Science 2020;367:392-396
Virolainen, S.J.; VonHandorf, A.; Viel, K.; Weirauch, M.T.; Kottyan, L.C. Gene-environment interactions and their impact on human health. Genes Immun 2023;24:1-11
Virtanen, S.M.; Nevalainen, J.; Kronberg-Kippila, C.; Ahonen, S.; Tapanainen, H.; Uusitalo, L.; Takkinen, H.M.; Niinisto, S.; Ovaskainen, M.L.; Kenward, M.G.; Veijola, R.; Ilonen, J.; Simell, O.; Knip, M. Food consumption and advanced beta cell autoimmunity in young children with HLA-conferred susceptibility to type 1 diabetes: a nested case-control design. Am J Clin Nutr 2012;95:471-478
Wang, M.; Rang, O.; Liu, F.; Xia, W.; Li, Y.; Zhang, Y.; Lu, S.; Xu, S. A systematic review of metabolomics biomarkers for Bisphenol A exposure. Metabolomics 2018;14:45
Weis, M. Impact of the gut microbiome in cardiovascular and autoimmune diseases. Clin Sci (Lond) 2018;132:2387-2389
Wilson, J.C.; Furlano, R.I.; Jick, S.S.; Meier, C.R. Inflammatory Bowel Disease and the Risk of Autoimmune Diseases. J Crohns Colitis 2016;10:186-193
Xia, J.; Wishart, D.S. MetPA: a web-based metabolomics tool for pathway analysis and visualization. Bioinformatics 2010;26:2342-2344
Xu, J.; Huang, G.; Guo, T.L. Bisphenol S Modulates Type 1 Diabetes Development in Non- Obese Diabetic (NOD) Mice with Diet- and Sex-Related Effects. Toxics 2019;7

#### **Figure captions** 722

Fig. 1. Summary of our work, which aimed to investigate how prenatal exposure to 723 environmental contaminants alters the cord serum metabolome in the ABIS cohort. We used 724 metabolomics to determine the levels of exposure to environmental contaminants and metabolites 725 in the cord blood. Our work involved three main stages. Firstly, we examined the levels of 726 exposure and significant differences between control (N = 268) and cases (N = 62). Secondly, we 727 studied the associations of contaminant exposure with cord serum metabolic profiles. Finally, we 728 investigated the impact of contaminant exposure on cord serum metabolites. Overall, our work 729 sheds light on the effects of environmental contaminants on the cord serum metabolome, which 730 may have implications for the future progression of autoimmune diseases. 731

Fig. 2. Box plots that illustrate the levels of selected contaminants in control and cases. The 732 violin plots (A-F) on top of the box plots depict the distribution of the selected contaminants (log2 733 intensities). To test the mean difference between the control and cases, we conducted a Wilcoxon 734 test. The p-values are provided to indicate the significance levels for the mean differences between 735 the two groups for each contaminant (A-F). Specifically, p < 0.05 indicates statistical significance, 736 and p < 0.1 suggests a trend toward significance. Overall, these results help to identify specific 737 contaminants that may contribute to the altered cord serum metabolome in cases. 738

Fig. 3. Correlation plots that depict the relationships between contaminant exposure, 739 metabolite clusters, and demographic data in controls (A) and cases (B). We used pairwise 740 Spearman correlation to calculate the correlation coefficients between all cluster variables, 741 742 contaminants, and demographic variables in the ABIS cohort. Positive and negative correlations are denoted by blue and red colours, respectively. The size of the dot in each cell corresponds to 743 744 the strength of the pairwise correlation. To improve visualization, we only show correlations between +/-0.20 to 1.0 in the plots. Overall, these correlation plots provide a comprehensive 745

overview of the complex relationships between environmental contaminants, metabolites, anddemographic factors in the ABIS cohort.

Fig. 4. Partial correlation network in the form of a chord diagram that shows the associations 748 between contaminant exposure, metabolite clusters, and demographic data in controls (A) 749 and cases (B). To filter out spurious or indirect correlations between variables, we used the 750 Debiased Sparse Partial Correlation (DSPC) algorithm (Basu et al. 2017) to only show direct 751 correlations. We used a conservative cut-off between +/- 0.14 to 1.0 to visualize the correlations 752 and project only correlations across groups (Contaminants, metabolite clusters, and 753 covariates/demographic data). Positive and negative correlations are denoted by blue and red lines, 754 respectively. Overall, this partial correlation network provides a more detailed view of the complex 755 756 relationships between environmental contaminants, metabolites, and demographic factors in the ABIS cohort. 757

Fig. 5. Impact of environmental contaminants on cord serum metabolites. Horizontal bar plots 758 (A, D, G) and (C, F, I) display the ranks of contaminants as predictors of metabolite clusters (PC2, 759 PC11, and LC6) and individual metabolites (Tryptophan, 3-Chlorothieno [2,3-b]thiophene-2-760 carbonyl chloride, and TG(16:0/18:2/18:2)), respectively. The potential impact of contaminants 761 on metabolite clusters or individual metabolites is determined by their rank at the top of the bar 762 plot. The ranks are based on their absolute normalized (ridge) regression coefficients. Violin plots 763 (B, E, H) show the levels of metabolites (clusters) associated with levels of exposure to 764 contaminants from contaminants clusters 1 (CC1) and 3 (CC3). The violin plot represents the 765 density of the sample within each quartile, and their distribution is represented using a box plot at 766 the centre. Two-way ANOVA followed by post-hoc Tukey's HSD test was used to compare the 767 mean difference between levels of metabolites (along quartiles). 768

**Fig. 6. Pathway enrichment analysis comparing cases versus controls for Deoxynivalenol** (**DON**) **impact polar metabolites.** The scatter plots depict the p-values using two different pathway maps: MFN pathway maps on the left panels and KEGG pathway maps on the right

772	panels. The pathway analysis methods Mummichog and GSEA are used on the y-axis and x-axis,
773	respectively, for both control (A, B) and cases (C, D). The size of the circle on each scatter plot
774	represents the pathway impact value. For more detailed information, such as the number of
775	metabolites in the pathways (total number/hits/significant hits) and p-values, please refer to the
776	supplementary information.

777

#### Fig. 1 779



**Fig. 2** 781



#### Fig. 3 783



#### Fig. 4 785



#### Fig. 5 787



#### Fig. 6



# Prenatal exposure to environmental contaminants is associated with altered cord serum metabolite profiles in future immune-mediated diseases

**Supplementary Material** 



Fig. S1. Box plots that show the levels of selected contaminants in the ABIS cohort at the individual disease levels. The violin plots (A-D) on top of the box plots illustrate the distribution of the selected contaminants (log2 intensities). To compare multiple group means, we used the Kruskal-Wallis Test, and for pairwise comparison against the reference (Control), we used the Wilcoxon Test. The p-values are provided to indicate the significance levels for the mean differences between the two groups (control vs. cases) for each contaminant (A-D). Specifically, p < 0.05 indicates statistical significance, and p < 0.1 suggests a trend toward significance. CD, HT, IBD, JIA, and T1D refer to Celiac disease, Hypothyroidism, Crohn's disease, Juvenile Idiopathic Arthritis and Type 1 Diabetes respectively.



Fig. S2. Classification of controls and immune-mediated diseases using contaminant exposure as predictors. In panel A, the ranks of the predictors (contaminants) obtained from the Logistic ridge regression (LRR) model, adjusted by Z-Score, Maternal age and BMI, are presented. The greatest contributing contaminants (predictors) that aided in the classification of control vs. cases (mean AUC = 0.65, 95% CI: 0.63-0.67) are shown at the top of the chart. In panel B, the Receiver Operating Characteristic (ROC) and AUC values from stepwisepredictive LRR models (10-fold cross-validation) are shown. An optimal set of five contaminants (predictors) (AUC = 0.67, 95% CI: 0.66-0.68) associated with the classification of control vs. cases are presented.



Fig. S3. Association between exposure to environmental contaminants and the alteration of cord serum metabolites. The bar plots (A-F) show the linear predictors of changes in cord serum metabolite profiles, which are analysed in the form of metabolite clusters (Polar metabolite and lipid clusters). At the top of each bar plot (A-F), the most contributing contaminants (predictors) associated with selected metabolite clusters are shown. The ranks of the predictors are based on their absolute normalized (ridge) regression coefficients. The bar plots (A-D) represent the contaminant exposure as linear predictors of changes in polar metabolite clusters PC1, PC4, PC6 and PC10, while the bar plots (E-F) represent the contaminant exposure as linear predictors of changes in lipid clusters LC1 and LC3.

			Level of
Full name	Abbreviation	Cluster	identification
Bisphenol S	BPS	CC1	Level 1
Deoxynivalenol	DON	CC1	Level 1
Monobutyl phthalate	MBP	CC1	Level 2
Perfluorodecanoic acid	PFDA	CC1	Level 1
Methylperfluorooctane sulfonamidoacetic		CC1	Level 2
acid	MeFOSAA		
Environmental Contaminant 1	EC1	CC1	Level 2
Environmental Contaminant 2	EC2	CC1	Level 2
a-Zearalanol	ZEL	CC1	Level 1
Ethylparaben	EP	CC2	Level 1
Methylparaben	MP	CC2	Level 1
Propylparaben	PP	CC2	Level 1
Perfluorohexanesulfonic acid Branched	PFHxSBr	CC3	Level 1
Perfluorohexanesulfonic acid	PFHxS	CC3	Level 1
Perfluorooctanoic acid Branched 1	PFOABr1	CC4	Level 1
Perfluorooctanoic acid Linear 1	PFOAL1	CC4	Level 1
Perfluorooctanoic acid Branched 2	PFOABr2	CC4	Level 1
Perfluorooctanoic acid Linear 2	PFOAL2	CC4	Level 1
Perfluorooctanesulfonic acid Branched	PFOSBr	CC4	Level 1
Perfluorooctanesulfonic acid	PFOS	CC4	Level 1
Environmental Contaminant 3	EC3	CC4	Level 2

Table S1. List of contaminants, clusters and their level of identification based on the Metabolomics Standards Initiative (MSI).

Table S2. Two-way analysis of variance (ANOVA) for cord serum lipids (cluster LC1 to LC8) impacted by contaminants exposure (Contaminant cluster CC1 to CC4). The samples were grouped based on contaminants exposure quartiles (1 to 4) and Groups (Control/Cases). The statistical significance levels are represented by p-values (p < 0.05 marked bold, p-values < 0.1in italics).

Contominant		Factor 1:	Factor 2:	Interestions
Contaminant	Lipid cluster	Contaminant	Groups	E1*E2
cluster		quartiles	(Control, Cases)	F1*F2
CC1	LC1	0.291	0.203	0.467
CC1	LC2	0.271	0.674	0.568
CC1	LC3	9.59×10 <sup>-4</sup>	0.884	0.701
CC1	LC4	6.95×10 <sup>-4</sup>	0.983	0.850
CC1	LC5	0.519	0.055	0.064
CC1	LC6	0.265	0.124	0.111
CC1	LC7	2.03×10 <sup>-2</sup>	0.919	0.936
CC1	LC8	0.869	0.449	0.260
CC2	LC1	0.706	0.195	0.895
CC2	LC2	0.683	0.719	0.471
CC2	LC3	0.814	0.901	0.992
CC2	LC4	0.531	0.973	0.958
CC2	LC5	0.995	0.071	0.947
CC2	LC6	0.731	0.176	0.608
CC2	LC7	0.096	0.960	0.139
CC2	LC8	0.298	0.378	0.917
CC3	LC1	0.578	0.220	0.721
CC3	LC2	0.283	0.803	0.856
CC3	LC3	0.276	0.981	0.730
CC3	LC4	0.581	0.840	0.747
CC3	LC5	1.43×10 <sup>-4</sup>	0.061	0.433
CC3	LC6	3.27×10 <sup>-3</sup>	0.194	0.329
CC3	LC7	0.909	0.967	0.160
CC3	LC8	0.179	0.455	0.919
CC4	LC1	0.249	0.141	0.074
CC4	LC2	0.246	0.534	0.416
CC4	LC3	0.194	0.713	0.027
CC4	LC4	0.221	0.868	0.032
CC4	LC5	0.019	0.026	0.068
CC4	LC6	0.361	0.123	0.348
CC4	LC7	0.172	0.774	0.521
CC4	LC8	0.095	0.296	0.523

medRxiv preprint doi: https://doi.org/10.1101/2023.11.10.23298353; this version posted November 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in pernetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

**Table S3.** Post-Hoc test that followed a two-way analysis of variance for cord serum lipids (cluster LC1 to LC8) affected by contaminant exposure (Contaminant cluster CC1 to CC4). The Post-Hoc Tukeys' HSD test was used for pairwise comparison between metabolite levels (along quartiles). The statistical significance levels are indicated by p-values, with values less than 0.05 marked in bold and values less than 0.1 in italics.

Contaminant	Lipid	Factor 1: Contaminant quartiles					
cluster	cluster	Q2-Q1	Q3-Q1	Q4-Q1	Q3-Q2	Q4-Q2	Q4-Q3
CC1	LC1	1.000	0.379	0.762	0.371	0.755	0.925
CC1	LC2	0.407	0.820	0.271	0.905	0.994	0.785
CC1	LC3	0.317	0.106	3.68×10 <sup>-4</sup>	0.942	0.091	0.289
CC1	LC4	0.166	0.081	2.38×10 <sup>-4</sup>	0.988	0.156	0.292
CC1	LC5	0.991	0.904	0.866	0.980	0.711	0.467
CC1	LC6	0.216	0.659	0.911	0.864	0.585	0.962
CC1	LC7	0.759	0.154	0.018	0.675	0.204	0.837
CC1	LC8	0.988	0.870	0.915	0.971	0.987	0.999
CC2	LC1	0.929	0.952	0.992	0.665	0.988	0.849
CC2	LC2	0.957	0.633	0.864	0.903	0.993	0.977
CC2	LC3	0.986	0.935	0.992	0.788	0.926	0.990
CC2	LC4	0.993	0.694	0.943	0.523	0.839	0.952
CC2	LC5	1.000	0.998	0.998	0.997	0.997	1.000
CC2	LC6	0.968	0.798	0.745	0.968	0.946	1.000
CC2	LC7	0.148	0.989	0.325	0.277	0.975	0.516
CC2	LC8	0.995	0.341	0.640	0.483	0.786	0.961
CC3	LC1	0.609	0.625	0.862	1.000	0.971	0.975
CC3	LC2	0.807	0.220	0.914	0.731	0.995	0.585
CC3	LC3	0.870	0.943	0.729	0.997	0.277	0.384
CC3	LC4	1.000	0.985	0.756	0.977	0.787	0.539
CC3	LC5	0.216	0.343	4.93×10 <sup>-5</sup>	0.994	0.048	0.024
CC3	LC6	0.490	0.273	0.001	0.979	0.101	0.231
CC3	LC7	0.999	0.983	0.986	0.953	0.998	0.893
CC3	LC8	0.299	0.702	0.174	0.910	0.991	0.772
CC4	LC1	0.969	0.655	0.629	0.376	0.353	1.000
CC4	LC2	0.759	0.826	0.178	0.999	0.718	0.646
CC4	LC3	0.863	0.462	0.167	0.903	0.573	0.932
CC4	LC4	0.812	0.727	0.157	0.999	0.620	0.718
CC4	LC5	0.984	0.215	0.139	0.101	0.059	0.996
CC4	LC6	0.999	0.881	0.470	0.818	0.389	0.895
CC4	LC7	0.993	0.504	0.449	0.345	0.300	1.000
CC4	LC8	0.928	0.754	0.315	0.379	0.093	0.886

Table S4. Two-way analysis of variance (ANOVA) for cord serum polar metabolites (cluster PC1 to PC12) impacted by contaminants exposure (Contaminant cluster CC1 to CC4). The samples were grouped based on contaminants exposure quartiles (1 to 4) and Groups (Control/Cases). The statistical significance levels are represented by p-values (p < 0.05 marked bold, p-values < 0.1 in italics).

Contaminant cluster	Polar metabolite cluster	Factor 1: Contaminant quartiles	Factor 2: Groups (Control, Cases)	Interactions F1*F2
CC1	PC1	<2×10 <sup>-16</sup>	0.685	0.331
CC1	PC2	<2×10 <sup>-16</sup>	0.022	0.516
CC1	PC3	0.780	0.237	0.380
CC1	PC4	3.11×10 <sup>-11</sup>	0.001	0.876
CC1	PC5	0.026	0.554	0.401
CC1	PC6	<2×10 <sup>-16</sup>	0.338	0.378
CC1	PC7	0.017	0.726	0.533
CC1	PC8	0.082	0.963	0.533
CC1	PC9	0.085	0.703	0.824
CC1	PC10	1.23×10 <sup>-11</sup>	0.967	0.731
CC1	PC11	4.09×10 <sup>-9</sup>	3.98×10 <sup>-4</sup>	0.544
CC1	PC12	0.068	0.356	0.824
CC2	PC1	0.025	0.574	0.186
CC2	PC2	1.89×10 <sup>-4</sup>	0.097	0.817
CC2	PC3	0.836	0.250	0.723
CC2	PC4	0.021	0.004	0.637
CC2	PC5	0.338	0.498	0.789
CC2	PC6	0.001	0.236	0.446
CC2	PC7	0.006	0.735	0.122
CC2	PC8	0.006	0.631	0.091
CC2	PC9	0.718	0.577	0.250
CC2	PC10	0.051	0.727	0.567
CC2	PC11	0.469	0.004	0.793
CC2	PC12	0.162	0.310	0.011
CC3	PC1	2.02×10 <sup>-6</sup>	0.589	0.829
CC3	PC2	0.131	0.199	0.550
CC3	PC3	0.115	0.259	0.665
CC3	PC4	0.044	0.011	0.515
CC3	PC5	0.095	0.538	0.396
CC3	PC6	0.017	0.160	0.273
CC3	PC7	0.509	0.738	0.004
CC3	PC8	0.002	0.809	0.628
CC3	PC9	0.905	0.591	0.232
CC3	PC10	0.094	0.554	0.953
CC3	PC11	0.044	0.005	0.384
CC3	PC12	0.822	0.318	0.148
CC4	PC1	0.242	0.468	0.861

CC4	PC2	0.376	0.118	0.678
CC4	PC3	0.034	0.143	0.855
CC4	PC4	0.138	0.002	0.666
CC4	PC5	0.027	0.273	0.473
CC4	PC6	0.001	0.398	0.617
CC4	PC7	0.686	0.833	0.032
CC4	PC8	0.010	0.427	0.090
CC4	PC9	0.659	0.738	0.525
CC4	PC10	0.019	0.621	0.943
CC4	PC11	0.183	0.002	0.677
CC4	PC12	0.579	0.401	0.006

Table S5. Post-Hoc test that followed a two-way analysis of variance for cord serum polar metabolites (cluster PC1 to PC12) affected by contaminant exposure (Contaminant cluster CC1 to CC4). The Post-Hoc Tukeys' HSD test was used for pairwise comparison between metabolite levels (along quartiles). The statistical significance levels are indicated by p-values, with values less than 0.05 marked in bold and values less than 0.1 in italics.

Contaminant	Polar	Factor 1: Contaminant quartiles					
cluster	metabolite cluster	Q2-Q1	Q3-Q1	Q4-Q1	Q3-Q2	Q4-Q2	Q4-Q3
CC1	PC1	0.002	10 <sup>-8</sup>	10 <sup>-8</sup>	0.021	10-8	0.006
CC1	PC2	10-8	10 <sup>-8</sup>	10 <sup>-8</sup>	0.813	10 <sup>-8</sup>	0.004
CC1	PC3	1.000	0.862	0.998	0.875	0.997	0.773
CC1	PC4	4×10 <sup>-7</sup>	1.84×10 <sup>-4</sup>	10 <sup>-8</sup>	0.571	0.357	0.020
CC1	PC5	0.494	0.653	0.014	0.995	0.362	0.242
CC1	PC6			8.78×10 <sup>-</sup>	9.06×10 <sup>-</sup>	5.71×10 <sup>-</sup>	
		4.76×10 <sup>-10</sup>	9.10×10 <sup>-13</sup>	13	4	7	0.362
CC1	PC7	0.539	0.853	0.011	0.951	0.288	0.100
CC1	PC8	0.139	0.321	0.096	0.972	0.998	0.930
CC1	PC9	1.000	0.603	0.533	0.665	0.471	0.051
CC1	PC10	2.4×10 <sup>-6</sup>	7×10 <sup>-7</sup>	10-8	0.993	0.155	0.262
CC1	PC11	1.71×10 <sup>-5</sup>	1.93×10 <sup>-4</sup>	10-8	0.950	0.346	0.127
CC1	PC12	0.922	0.918	0.218	0.581	0.564	0.052
CC2	PC1	0.072	0.035	0.690	0.992	0.543	0.375
CC2	PC2						3.40×10 <sup>-</sup>
		0.998	0.938	0.003	0.869	0.006	4
CC2	PC3	0.978	0.798	0.988	0.957	1.000	0.936
CC2	PC4	0.707	0.974	0.020	0.918	0.252	0.064
CC2	PC5	0.615	0.288	0.877	0.944	0.966	0.737
CC2	PC6	0.066	0.075	0.913	1.000	0.011	0.012
CC2	PC7	0.812	0.522	0.158	0.113	0.621	0.004
CC2	PC8	0.116	0.013	0.011	0.844	0.814	1.000
CC2	PC9	0.988	0.990	0.851	0.923	0.963	0.685
CC2	PC10	0.721	0.669	0.548	1.000	0.085	0.070
CC2	PC11	0.806	0.501	0.998	0.958	0.886	0.610
CC2	PC12	0.883	0.898	0.463	0.481	0.887	0.140
CC3	PC1			5.92×10 <sup>-</sup>		4.08×10 <sup>-</sup>	
		0.967	0.002	5	0.008	4	0.850
CC3	PC2	0.125	0.585	0.240	0.790	0.989	0.929
CC3	PC3	0.734	0.495	0.076	0.981	0.506	0.748
CC3	PC4	0.473	0.509	0.983	0.026	0.272	0.741
CC3	PC5	0.924	0.109	0.292	0.359	0.664	0.960
CC3	PC6	0.633	0.325	0.009	0.956	0.199	0.464
CC3	PC7	0.987	0.919	0.721	0.764	0.512	0.977
CC3	PC8	0.820	0.030	0.005	0.229	0.065	0.940
CC3	PC9	0.994	0.996	0.886	1.000	0.965	0.957
CC3	PC10	0.114	0.619	0.149	0.737	0.999	0.803
CC3	PC11	0.601	0.443	0.866	0.034	0.185	0.891

CC3	PC12	0.997	0.800	0.986	0.893	0.999	0.943
CC4	PC1	0.479	0.196	0.713	0.945	0.983	0.794
CC4	PC2	0.988	0.939	0.710	0.994	0.508	0.359
CC4	PC3	0.597	0.854	0.383	0.174	0.025	0.859
CC4	PC4	0.994	0.975	0.229	0.908	0.139	0.453
CC4	PC5	0.981	0.146	0.060	0.302	0.147	0.982
CC4	PC6	0.806	1.000	0.019	0.820	0.001	0.018
CC4	PC7	1.000	0.761	0.934	0.726	0.914	0.980
CC4	PC8	0.637	0.065	0.011	0.565	0.217	0.922
CC4	PC9	0.997	1.000	0.678	0.999	0.801	0.730
CC4	PC10	0.976	0.036	1.000	0.102	0.972	0.035
CC4	PC11	0.918	0.716	0.738	0.975	0.347	0.165
CC4	PC12	0.925	0.998	0.867	0.859	0.505	0.931

Table S6. provides information on the pathways identified through pathway enrichment analysis using MFN pathway maps for controls. It includes the pathways, their corresponding p-values, and the number of metabolites in each pathway, including the total size, hits, and significant hits. The combined p-value was calculated by combining GSEA and Mummichog scores. This table lists only those pathways that have a combined p-value of less than 0.05.

		Hits	Significant	Mummichog	GSEA	Combined
Name of the	Total		hits	P values	P	P values
pathways	size	50	40	0.0207	values	0.00105
Tyrosine metabolism	160	50	40	0.0207	0.0099	0.00195
metabolism	94	31	26	0.02223	0.0198	0.00384
Valine, leucine and isoleucine degradation	65	12	11	0.049	0.0101	0.00426
Pyrimidine metabolism	70	20	17	0.05297	0.0099	0.00449
Urea cycle/amino group metabolism	85	26	21	0.07829	0.01	0.00638
Glycine, serine, alanine and threonine metabolism	88	27	21	0.1365	0.01	0.01037
Butanoate metabolism	34	11	10	0.06911	0.02083	0.01086
Beta-Alanine metabolism	20	9	8	0.1347	0.01099	0.01112
Caffeine metabolism	11	4	4	0.1909	0.01176	0.01594
Fructose and mannose metabolism	33	7	7	0.05475	0.04301	0.01661
Sialic acid metabolism	107	14	11	0.2462	0.01	0.01725
Aminosugars metabolism	69	10	8	0.286	0.01064	0.02068
Propanoate metabolism	31	9	8	0.1347	0.03297	0.02849
Pyruvate Metabolism	20	11	8	0.4575	0.01099	0.03164
Hexose phosphorylation	20	10	7	0.5454	0.01099	0.03667
Methionine and cysteine metabolism	94	17	14	0.1189	0.05941	0.04206
Glutamate metabolism	15	9	8	0.1347	0.05495	0.04371
Selenoamino acid metabolism	35	6	5	0.3404	0.02222	0.04451
Histidine metabolism	33	10	9	0.09685	0.08511	0.0478
Glycosphingolipid metabolism	67	20	15	0.2781	0.0297	0.04787

Table S7. provides information on the pathways identified through pathway enrichment analysis using KEGG pathway maps for controls. It includes the pathways, their corresponding p-values, and the number of metabolites in each pathway, including the total size, hits, and significant hits. The combined p-value was calculated by combining GSEA and Mummichog scores. This table lists only those pathways that have a combined p-value of less than 0.05.

		Hits	Significant	Mummichog	GSEA	Combined
Name of the	Total		hits	P values	Р	P values
pathways	size				values	
Aminoacyl-tRNA	22	14	14	0.0072	0.0101	0.00077
biosynthesis		17	17	0.0072	0.0101	0.00077
Glycine, serine and	30	14	14	0.0072	0.0101	0.00077
threonine metabolism	50	14	14	0.0072	0.0101	0.00077
Tyrosine metabolism	42	21	19	0.02887	0.0099	0.00262
Fructose and mannose	20	6	6	0 1235	0.0105	0.00004
metabolism	20	0	0	0.1233	3	0.00994
Valine, leucine and					0.0105	
isoleucine	8	6	6	0.1235	0.0105	0.00994
biosynthesis					5	
Valine, leucine and	35	10	Q	0.158	0.0101	0.01188
isoleucine degradation	55	10	,	0.150	0.0101	0.01100
Phenylalanine	10	8	7	0.2676	0.0101	0.01860
metabolism	10	0	/	0.2070	0.0101	0.01809
Phenylalanine,						
tyrosine and	4	3	3	0 3529	0.0133	0.02001
tryptophan	-	5	5	0.3327	3	0.02771
biosynthesis						
Amino sugar and						
nucleotide sugar	35	9	6	0.7479	0.0101	0.04446
metabolism						

Table S8. provides information on the pathways identified through pathway enrichment analysis using MFN pathway maps for cases. It includes the pathways, their corresponding pvalues, and the number of metabolites in each pathway, including the total size, hits, and significant hits. The combined p-value was calculated by combining GSEA and Mummichog scores. This table lists only those pathways that have a combined p-value of less than 0.05.

		Hits	Significant	Mummichog	GSEA	Combined
Name of the	Total		hits	P values	Р	P values
pathways	size				values	
Urea cycle/amino	85	21	0	0.04270	0.0105	0.00302
group metabolism	65	21	0	0.04279	3	0.00392
Beta-Alanine	20	0	5	0.01072	0.0246	0.0042
metabolism	20	9	5	0.01975	9	0.0042
Glutamate metabolism	15	8	4	0.05732	0.0125	0.0059
Glutathione	10	4	2	0.02771	0.0281	0.00627
Metabolism	19	4	5	0.02771	7	0.00037
Aminosugars	60	10	5	0.02216	0.0246	0.00664
metabolism	09	10	5	0.05510	9	0.00004
Valine, leucine and	65	11	5	0.05112	0.0232	0.0002
isoleucine degradation	05	11	5	0.03113	6	0.0092
Alanine and Aspartate	20	10	4	0 1225	0.0125	0.01154
Metabolism	50	10	4	0.1255	0.0123	0.01134
Pyruvate Metabolism	20	10	4	0.1235	0.0125	0.01154
Glycerophospholipid	156	01	7	0 1102	0.0210	0.01620
metabolism	130	21	/	0.1102	5	0.01039
Glycine, serine,					0.0106	
alanine and threonine	88	25	7	0.2259	0.0100	0.0169
metabolism					4	
Butanoata matabaliam	34	10	4	0 1225	0.0229	0.01040
	54	10	4	0.1233	9	0.01949
Carbon fivation	10	2	2	0.04075	0.0952	0.02543
	10	2	2	0.04075	4	0.02343
Aspartate and					0.0108	
asparagine	114	30	6	0.591	7	0.03885
metabolism					/	
Pyrimidine	70	18	6	0 1357	0.0543	0.04358
metabolism	70	10	0	0.1357	5	0.04338
Arginine and Proline	45	10	5	0 3361	0.0224	0.04445
Metabolism	43	17	5	0.5501	7	0.04445

Table S9. provides information on the pathways identified through pathway enrichment analysis using KEGG pathway maps for cases. It includes the pathways, their corresponding pvalues, and the number of metabolites in each pathway, including the total size, hits, and significant hits. The combined p-value was calculated by combining GSEA and Mummichog scores. This table lists only those pathways that have a combined p-value of less than 0.05.

		Hits	Significant	Mummichog	GSEA	Combined
Name of the	Total		hits	P values	Р	P values
pathways	size				values	
Aminoacyl-tRNA biosynthesis	22	15	7	0.03758	0.0109 9	0.00363
Glycine, serine and threonine metabolism	30	14	6	0.08186	0.0112 4	0.00735
Phosphonate and phosphinate metabolism	4	2	2	0.05452	0.0322 6	0.01291
Alanine, aspartate and glutamate metabolism	28	12	5	0.1234	0.0344 8	0.02749
Glyoxylate and dicarboxylate metabolism	31	7	3	0.2106	0.0229 9	0.03066
Pantothenate and CoA biosynthesis	17	5	3	0.0864	0.0588 2	0.03193
Glycolysis or Gluconeogenesis	23	3	2	0.1385	0.0428 6	0.03637
Arginine and proline metabolism	37	19	4	0.6919	0.0109 9	0.0447